Ligand Pharmaceuticals has signed a global license and supply agreement with Spectrum Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestones, as well as royalties on future sales of Captisol-enabled melphalan.   The Captisol-enabled melphalan program is currently in development for use as a conditioning tr...